Piper Jaffray analyst Edward Tenthoff raised his price target for Cytokinetics (CYTK) to $20 from $14 after the company presented Phase I data on its wholly-owned cardiac myosin inhibitor CK-274 for hypertrophic cardiomyopathy at this weekend's Heart Failure Society of America meeting. CK-274 was safe and well-tolerated in doses up to 75mg in 81 healthy adults with no observed serious adverse events, Tenthoff tells investors in a research note. CK-274 has a similar mechanism of action to MyoKardia's (MYOK) mavacamten and this weekend's Phase I data "largely de-risk" CK-274, says Tenthoff. He reiterates an Overweight rating on Cytokinetics.